Edgar Segura
Parkinson’s complaint (PD) is the alternate most common neurodegenerative complaint in aged individualities worldwide. Pharmacological treatment for such a complaint consists of medicines similar as monoamine oxidase B (MAO- B) impediments to increase dopamine attention in the brain. still, similar medicines have adverse responses that limit their use for extended ages; therefore, the design of lower poisonous and more effective composites may be explored. In this environment, cheminformatics and computational chemistry have lately contributed to developing new medicines and the hunt for new remedial targets. thus, through a data- driven approach, we used cheminformatic tools to find and optimize new composites with pharmacological exertion against MAO- B for treating PD. First, we recaptured from the literature 3316 original papers published between 2015 – 2021 that experimentally tested 215 natural composites against PD. From similar composites, we erected a pharmacological network that showed rosmarinic acid, chrysin, naringenin, and cordycepin as the most connected bumps of the network. From similar composites, we performed characteristic analysis and developed evolutionary libraries to gain new derived structures. We filtered these composites through a docking test against MAO- B and attained five deduced composites with advanced affinity and lead likeness eventuality. also we estimated its antioxidant and pharmacokinetic eventuality through a docking analysis (NADPH oxidase and CYP450) and physiologically- grounded pharmacokinetic (PBPK modeling). Interestingly, only one emulsion showed binary exertion (antioxidant and MAO- B impediments) and pharmacokinetic eventuality to be considered a possible seeker for PD treatment and farther experimental analysis.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi